Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Balversa | erdafitinib | locally advanced unresectable or metastatic urothelial carcinoma (UC) | Pending | |||
Dojolvi | triheptanoin | Long-chain fatty acid oxidation disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
Dysport Therapeutic | abobotulinumtoxinA | lower limb spasticity | Reimburse with clinical criteria and/or conditions | Complete | ||
Benlysta | belimumab | Lupus nephritis | Reimburse with clinical criteria and/or conditions | Complete | ||
Kanuma | sebelipase alfa | Lysosomal acid lipase deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Active | |||
Beovu | brolucizumab | Macular degeneration, age-related | Reimburse with clinical criteria and/or conditions | Complete | ||
Eylea | Aflibercept | Macular degeneration, age-related | List with criteria/condition | Complete | ||
Lucentis | Ranibizumab | Macular degeneration, age-related | List with clinical criteria and/or conditions | Complete | ||
Macugen | Pegaptanib sodium | Macular degeneration, age-related | Do not list | Complete |